This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
—a common threat across a wide range of interstitial lung diseases (ILDs), including connective tissue diseases (CTDs). Pulmonary fibrosis can become a key driver of irreversible harm and early mortality, and calls for urgent identification and intervention.1-4
Find out more about the Critical Threat
See what Clive Kelly, Senior Lecturer, has to say about the prevalence of pulmonary fibrosis in
patients with connective tissue diseases
Pulmonary fibrosis is an insidious, unpredictable threat.
Understand the pathophysiology of pulmonary fibrosis and hear an
expert's view on the threat across a range of ILDs.
1.
Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of ... in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212.
2.
Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362-370.
3.
Caban JJ, Yao J, Bagci U, Mollura DJ. Monitoring pulmonary fibrosis by fusing clinical, physiological, and computed tomography features. Conf Proc IEEE Eng Med Biol Soc. 2011;6216-6219.
4.
Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, on behalf of the IPF Consensus Working Group. What’s in a name? That which we call IPF, by any other name would act the same. Eur Resp J. 2018;51:1800692.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information on pulmonary fibrosis.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the US and UK and have read and understood this disclaimer.